Table 2: Characteristics of reported cases.

All cases, Survivors
Nonsurvivors at 5 months

Median age (years) 68 (56–85)69.5 (56–83) 67.5 (58–85) 0.84
Male/female 18/127/511/71.00
Diabetes 210.23
HTN 251.00
Hyperlipidemia 231.00
CAD 5110.26
CHF 380.39
>200 mg/<200 mg Amiodarone dose given18/125/713/50.33
Latency period 2.92 (0.5–12) 3.06 (0.5–5.5) 2.54 (1–12)0.45
Cumulative dose279.92 (55–1241)279.92 (55–657)465 (165–1241)0.07
Prothrombin time 16.76 (11–39) 13.68 (11–17) 18.92 (11–39) 0.08
Bilirubin (micromole/liter)55.73 (9–481)71.67 (9–481)46.16 (12–142)0.53
AST177.58 (64–734) 103.33 (38–317)216.88 (64–734)0.03
ALK P352.96 (73–1451)331.5 (73–1451)365.59 (119–854) 0.78
Albumin28 (11–39)31 (23–39)26.91 (11–38) 0.32
ALT134.59 (32–781)92.1 (32–237) 170 (35–781) 0.16
GGT 569 (133–1493)640.33 (230–1231)538.43 (133–1493)0.74

refers to the number of patients in each group. Not all studies had data on all variables.
Median values given for latency period, and for all other variables, mean values are given.